MeSH term
Frequency | Condition_Probility | Adolescent | 25 | 0.0 |
Adult | 41 | 0.0 |
Child | 41 | 0.0 |
Child, Preschool | 24 | 0.0 |
Comparative Study | 20 | 0.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Female | 74 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Humans | 225 | 0.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Infant | 21 | 0.0 |
Male | 64 | 0.0 |
Research Support, Non-U.S. Gov't | 180 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 84 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Ribosomal Protein S6/metabolism | 3 | 42.0 |
Ribosomal Protein S6 Kinases, 70-kDa/metabolism | 2 | 10.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Tuberous Sclerosis/genetics/metabolism/*pathology | 2 | 100.0 |
DNA Mutational Analysis | 21 | 0.0 |
Lasers | 2 | 1.0 |
Loss of Heterozygosity/genetics | 6 | 4.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Proteins/*genetics | 49 | 3.0 |
Blotting, Southern | 7 | 0.0 |
Cohort Studies | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Infant, Newborn | 5 | 0.0 |
*Mutation | 21 | 0.0 |
Phenotype | 15 | 0.0 |
Polymorphism, Single-Stranded Conformational | 29 | 1.0 |
Prospective Studies | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Tuberous Sclerosis/*genetics | 57 | 61.0 |
Variation (Genetics) | 2 | 0.0 |
Alleles | 8 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
DNA/metabolism | 3 | 0.0 |
Mutation | 38 | 0.0 |
Polymorphism, Genetic | 15 | 0.0 |
Temperature | 3 | 0.0 |
Time Factors | 5 | 0.0 |
Animals | 81 | 0.0 |
Loss of Heterozygosity | 22 | 2.0 |
Proteins/physiology | 2 | 1.0 |
Repressor Proteins/physiology | 2 | 5.0 |
Codon, Nonsense | 3 | 2.0 |
Exons | 12 | 0.0 |
Introns | 4 | 0.0 |
Japan | 5 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Repressor Proteins/genetics | 15 | 10.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Flow Cytometry | 6 | 0.0 |
Immunoblotting | 5 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Protein Kinases/metabolism | 6 | 1.0 |
Proteins/metabolism | 6 | 0.0 |
Repressor Proteins/metabolism | 4 | 2.0 |
Ribosomal Protein S6 Kinases/metabolism | 14 | 19.0 |
*Signal Transduction | 6 | 0.0 |
Bladder Neoplasms/*genetics | 7 | 8.0 |
Chromosomes, Human, Pair 9/*genetics | 8 | 7.0 |
Gene Expression | 6 | 0.0 |
*Genes, Tumor Suppressor | 20 | 1.0 |
Genetic Markers/genetics | 2 | 0.0 |
Middle Aged | 21 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Chromosomes, Human, Pair 9/genetics | 9 | 7.0 |
Genes, Tumor Suppressor | 35 | 4.0 |
*Loss of Heterozygosity | 4 | 1.0 |
Aged | 8 | 0.0 |
Microsatellite Repeats | 7 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Proteins/genetics | 16 | 2.0 |
*Tumor Suppressor Proteins | 6 | 0.0 |
*Ubiquitin-Protein Ligases | 4 | 0.0 |
Cell Division/*physiology | 2 | 1.0 |
Cell Line | 24 | 0.0 |
Proteins/genetics/*metabolism | 11 | 2.0 |
Rats | 30 | 0.0 |
Repressor Proteins/genetics/*metabolism | 15 | 7.0 |
Transfection | 19 | 0.0 |
Tuberous Sclerosis/*genetics/physiopathology | 4 | 80.0 |
Tumor Suppressor Proteins/genetics/metabolism | 2 | 6.0 |
Chromosomes, Human, Pair 16/genetics | 8 | 8.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Germ-Line Mutation | 3 | 0.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Repressor Proteins/*genetics | 42 | 16.0 |
Tuberous Sclerosis/genetics | 10 | 38.0 |
Fatal Outcome | 3 | 0.0 |
Immunohistochemistry | 22 | 0.0 |
Proteins/*genetics/metabolism | 10 | 3.0 |
Repressor Proteins/*genetics/metabolism | 11 | 17.0 |
Syndrome | 2 | 0.0 |
Tuberous Sclerosis/*genetics/metabolism/pathology | 2 | 100.0 |
English Abstract | 11 | 0.0 |
Protein Biosynthesis | 7 | 0.0 |
COS Cells | 10 | 0.0 |
Family Health | 2 | 0.0 |
Pedigree | 18 | 0.0 |
Protein Binding | 14 | 0.0 |
Proteins/genetics/metabolism | 7 | 3.0 |
Tuberous Sclerosis/*genetics/pathology | 9 | 75.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Repressor Proteins/genetics/metabolism | 2 | 2.0 |
Staining and Labeling | 2 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 2 | 1.0 |
Genetic Screening | 4 | 0.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Mutation, Missense/genetics | 3 | 1.0 |
Point Mutation/genetics | 2 | 0.0 |
X Chromosome/genetics | 2 | 1.0 |
Binding Sites | 8 | 0.0 |
COS Cells/cytology | 2 | 40.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Gene Deletion | 3 | 0.0 |
Genes, Tumor Suppressor/physiology | 4 | 8.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Molecular Chaperones | 2 | 20.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Mutation/*genetics | 5 | 0.0 |
Phosphorylation | 19 | 0.0 |
Plasmids | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Tuberous Sclerosis/*genetics/metabolism | 5 | 71.0 |
Amino Acid Substitution | 3 | 0.0 |
Repressor Proteins/*genetics/*metabolism | 2 | 7.0 |
Chromosome Mapping | 27 | 0.0 |
Rats, Inbred F344 | 5 | 1.0 |
Cell Cycle | 5 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Hela Cells | 13 | 0.0 |
Mice | 21 | 0.0 |
Models, Biological | 8 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Up-Regulation | 2 | 0.0 |
Carcinoma, Renal Cell/*genetics | 3 | 3.0 |
Kidney Neoplasms/*genetics | 6 | 2.0 |
Blotting, Western | 7 | 0.0 |
Cell Division | 9 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Signal Transduction | 14 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Brain/*pathology | 2 | 1.0 |
Hamartoma/pathology | 2 | 40.0 |
Tuberous Sclerosis/*pathology | 2 | 28.0 |
Diagnosis, Differential | 3 | 0.0 |
Tuberous Sclerosis/*diagnosis/genetics | 2 | 50.0 |
Binding Sites/genetics | 2 | 0.0 |
Protein Isoprenylation | 2 | 2.0 |
Repressor Proteins/*chemistry/genetics/*metabolism | 2 | 22.0 |
Tuberous Sclerosis/genetics/metabolism | 5 | 100.0 |
Hyperplasia | 2 | 0.0 |
Tuberous Sclerosis/genetics/*pathology | 4 | 80.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
Genotype | 9 | 0.0 |
Tuberous Sclerosis/*complications/*genetics | 3 | 75.0 |
Clone Cells | 2 | 0.0 |
*Germ-Line Mutation | 5 | 1.0 |
Hamartoma/*genetics | 4 | 36.0 |
Molecular Sequence Data | 34 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Precipitin Tests | 11 | 0.0 |
Base Sequence | 32 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Proteins/genetics/*physiology | 3 | 2.0 |
Repressor Proteins/genetics/*physiology | 3 | 8.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
DNA Primers | 13 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
*Point Mutation | 2 | 0.0 |
Cell Size/genetics | 2 | 12.0 |
*Drosophila Proteins | 4 | 0.0 |
Genes, Dominant | 8 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Rats, Mutant Strains | 3 | 4.0 |
Cell Size | 3 | 1.0 |
Drosophila | 3 | 0.0 |
*Protein-Serine-Threonine Kinases | 8 | 0.0 |
Genes, Tumor Suppressor/genetics | 4 | 2.0 |
Cell Size/*physiology | 2 | 25.0 |
Drosophila melanogaster/cytology/genetics/physiology | 2 | 100.0 |
Insulin/metabolism | 3 | 2.0 |
Mosaicism | 2 | 2.0 |
Photoreceptors, Invertebrate/*cytology/physiology/ultrastructure | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Genes, Tumor Suppressor/*genetics | 4 | 1.0 |
Carcinoma, Transitional Cell/*genetics | 2 | 6.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Zinc Fingers | 2 | 0.0 |
Pregnancy | 10 | 0.0 |
Proteins/*metabolism | 9 | 1.0 |
Repressor Proteins/*metabolism | 10 | 5.0 |
Tuberous Sclerosis/*metabolism/pathology | 4 | 80.0 |
3T3 Cells | 3 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Gestational Age | 2 | 0.0 |
Linkage (Genetics) | 10 | 0.0 |
DNA | 2 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Exons/genetics | 7 | 0.0 |
Lymphangiomyomatosis/complications/*genetics | 2 | 100.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Tuberous Sclerosis/complications/*genetics | 4 | 66.0 |
Heterozygote | 5 | 0.0 |
Nucleic Acid Denaturation | 2 | 2.0 |
Chromosomes, Artificial, Yeast | 4 | 0.0 |
Contig Mapping | 2 | 1.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Neurons/metabolism | 5 | 1.0 |
Amino Acid Sequence | 16 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Genetic Markers | 14 | 0.0 |
Tuberous Sclerosis/*genetics/*pathology | 4 | 80.0 |
Crosses, Genetic | 2 | 0.0 |
Disease Models, Animal | 7 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Kidney Neoplasms/*genetics/pathology | 2 | 2.0 |
*Ligases | 3 | 1.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Chromosomes, Human, Pair 9 | 8 | 4.0 |
Point Mutation | 7 | 0.0 |
Proteins/*genetics/physiology | 4 | 5.0 |
Repressor Proteins/*genetics/physiology | 3 | 21.0 |
Rabbits | 4 | 0.0 |
Repressor Proteins/*analysis | 2 | 28.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Tuberous Sclerosis/genetics/*metabolism | 3 | 50.0 |
Heteroduplex Analysis | 2 | 2.0 |
In Situ Hybridization | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Chromosomes, Human, Pair 16 | 6 | 4.0 |
Genetic Counseling | 2 | 1.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Exons/*genetics | 3 | 0.0 |
Sequence Deletion | 6 | 0.0 |
Kidney Tubules/metabolism | 2 | 6.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Brain/pathology | 6 | 1.0 |
Family | 3 | 0.0 |
Penetrance | 2 | 1.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Epilepsy/*genetics/pathology | 2 | 40.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
*Chromosomes, Human, Pair 9 | 21 | 8.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Models, Genetic | 5 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Biopsy | 3 | 0.0 |
Mutation/genetics | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Abnormalities/genetics | 2 | 10.0 |
Cerebral Cortex/*abnormalities | 2 | 25.0 |
Neurocutaneous Syndromes/*genetics | 2 | 100.0 |
Seizures/etiology | 2 | 10.0 |
Tuberous Sclerosis/complications/genetics | 3 | 75.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
Mutation, Missense | 2 | 0.0 |
RNA Splicing/*genetics | 2 | 2.0 |
*Disease Models, Animal | 3 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Brain/metabolism | 4 | 0.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
*Mosaicism | 2 | 3.0 |
Point Mutation/*genetics | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Neurofilament Proteins/metabolism | 2 | 3.0 |
Cell Differentiation | 3 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Kidney/pathology | 2 | 1.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Haplotypes/genetics | 2 | 0.0 |
Mosaicism/*genetics | 2 | 5.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Tuberous Sclerosis/*metabolism | 2 | 50.0 |
Mental Retardation/genetics | 3 | 2.0 |
Microscopy, Confocal | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Repressor Proteins/*physiology | 4 | 3.0 |
*Chromosomes, Human, Pair 16 | 6 | 2.0 |
Down-Regulation | 3 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Monomeric GTP-Binding Proteins/*metabolism | 3 | 20.0 |
Neuropeptides/*metabolism | 4 | 4.0 |
Protein Kinases/*metabolism | 5 | 1.0 |
Sirolimus/pharmacology | 5 | 6.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Genetic Techniques | 2 | 2.0 |
Gene Silencing | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Proteins/chemistry/genetics | 2 | 7.0 |
Hamsters | 2 | 0.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Brain Chemistry | 2 | 0.0 |
Genes, Structural/genetics | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Repressor Proteins/genetics/physiology | 2 | 14.0 |
Drosophila Proteins/genetics/metabolism | 2 | 10.0 |
Carrier Proteins/metabolism | 7 | 0.0 |
Phosphoproteins/metabolism | 7 | 1.0 |
Cosmids/*genetics | 3 | 23.0 |
*Alleles | 2 | 0.0 |
*Heterozygote | 2 | 0.0 |
Fetus | 2 | 0.0 |
Angiomyolipoma/genetics | 2 | 66.0 |
*Chromosome Deletion | 4 | 0.0 |
Tuberous Sclerosis/etiology/*genetics | 2 | 100.0 |
Conserved Sequence | 3 | 0.0 |
Lod Score | 4 | 0.0 |
*Oncogenes | 3 | 0.0 |
Cosmids | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Dopamine beta-Hydroxylase/genetics | 2 | 7.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
14-3-3 Proteins | 4 | 2.0 |
Gene Expression Profiling | 2 | 0.0 |
Protein Kinases/*physiology | 3 | 5.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
Cell Proliferation | 3 | 1.0 |
Proteins/*physiology | 2 | 1.0 |
Proteins/genetics/physiology | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 2 | 3.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Proteins/*genetics/pharmacology | 3 | 42.0 |
Repressor Proteins/*genetics/pharmacology | 3 | 100.0 |
Tuberous Sclerosis/*complications/genetics | 2 | 100.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Cell Cycle/physiology | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Drosophila melanogaster/genetics/growth & development/metabolism | 2 | 66.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
